Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc N.MMED.WA


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Comment by TeddyTenBagson Feb 11, 2021 10:25am
270 Views
Post# 32537114

RE:RE:RE:$30 up in one day coming

RE:RE:RE:$30 up in one day comingYou're out to lunch pal. Stop spewing this garbage. There won't be a short squeeze on this stock any time soon. Current short volume is 946,200 shares, which is less than 1% of the total share count for the company. Stop trying to pull one over on inexperienced traders and pump the stock.

For anyone on this board, let the science and R&D take this stock where it needs to go. Literally a boom or bust stock. Always do your own research and never take advice at face value from someone on this board.

maysteeler23 wrote:

Shorts were warned with GME,  but they didn't learn.  1.5 million new short shares were added from dec 31 2020- jan 15 2021.  An increase of 66%.

https://www.marketbeat.com/stocks/OTCMKTS/MMEDF/short-interest/

A total of about 3 million shares were added from dec 2020 -Jan 15.  Who knows how much it is now?

You 2x the share price and you wipe about about 3 million short shares.  They will have to cover and won't have the money to cover it.


Then you raise the asks to $30 and blast the share price with $500-$1000 after the double.  And you cause a short death spiral.

If you're short GET OUT!!!  Cause a storm is coming.  $30+;)



<< Previous
Bullboard Posts
Next >>